Skip To Main Content
Virginijus Barzda on Muck Rack

Virginijus Barzda

As seen in: Nature, ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Virginijus

Contact Virginijus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pre-existing venous structural remodeling and arteriovenous fistula maturation assessed by conventional histology and nonlinear optical microscopy

|
By Lukas Kontenis, Mykolas Maciulis, Birutė Vaišnytė, Edvardas Žurauskas, Virginijus Barzda, Marius Miglinas, Viltė Gabrielė Samsonė, Danielius Samsonas, Simonas Jonas Norvydas, Petras Purlys
| Nature Verified
Abstract Arteriovenous fistula (AVF) nonmaturation remains a significant clinical challenge in hemodialysis patients. Pre-existing structural alterations of the venous wall, including fibrosis and extracellular matrix remodeling, may impair adaptive outward remodeling of the outflow vein after arterialization.
Open in Who Shared Issue with article?

Double Stokes polarimetric microscopy for chiral fibrillar aggregates - Scientific Reports

|
By Virginijus Barzda
| Nature Verified
Abstract Second harmonic generation (SHG) microscopy is a powerful tool for imaging collagen and other noncentrosymmetric fibrillar structures in biological tissue. Polarimetric SHG measurements provide ultrastructural information about the fibrillar organization in a focal volume (voxel).
Open in Who Shared Issue with article?

The physical landscape of CAR-T synapse

|
By Roshni Basu, Morgan Huse, Mehdi Alizadeh, Virginijus Barzda
| ScienceDirect Verified
Section snippets Significance Chimeric antigen receptor (CAR)-T therapy achieved unprecedented success in treating refractory blood cancers. However, major challenges exist that restrict its broader applications against solid tumors. The rational design of new CAR-Ts with improved anti-tumor function requires an in-depth understanding of how CAR-Ts interact with tumor targets, which is currently lacking.
Open in Who Shared Issue with article?
See all 4 articles